Summary by Moomoo AI
WUXI PHARMACEUTICAL MING KAND NEW DRUG DEVELOPMENT CO., LTD. CONDUCTED A SERIES OF SHARE REPURCHASE ACTIVITIES FROM MARCH 11 TO 19, 2024, WITH A TOTAL OF 2,797,126 SHARES OF A SHARES. The repurchase activities carried out by the company on the Shanghai Stock Exchange did not write off the repurchased shares. Under the Listing Rules of the Hong Kong Stock Exchange Limited, companies are required to disclose changes in issued share capital. The price of the repurchased shares ranged from RMB 51.07 to RMB 57.32, while the total amount of the repurchases reached RMB 20,095,471.8. Director Li Gem confirmed that all repurchase activities have been formally authorized by the Board of Directors and comply with the relevant legal requirements.